share_log

三葉草生物-B：自願公告 三葉草生物公布二價RSV候選疫苗SCB-1019 I 期臨床試驗 首批年輕成年人群組 獲得積極初步數據

CLOVER BIO-B: VOLUNTARY ANNOUNCEMENT CLOVER ANNOUNCES POSITIVE PRELIMINARY PHASE I RESULTS FOR BIVALENT RSV VACCINE CANDIDATE SCB-1019 IN INITIAL YOUNG ADULT COHORT

香港交易所 ·  Apr 8 05:02
Summary by Moomoo AI
三葉草生物-B（股份代號：2197）自願公告其開發的二價RSV候選疫苗SCB-1019在I期臨床試驗中獲得積極初步數據。該試驗在澳大利亞進行，旨在評估該疫苗在不同年齡群組中的安全性、反應原性和免疫原性。首批年輕成年人群組（18-59歲）接種SCB-1019後，對RSV A和RSV B中和抗體的幾何平均滴度（GMTs）和幾何倍數升高（GMFRs）顯示出顯著提升，而安慰劑組則無明顯變化。這些數據顯示SCB-1019在免疫原性方面相較於其他蛋白亞單位RSV疫苗表現出相當或更優的效果。此外，該疫苗在首批受試者中未觀察到任何明顯的安全性或反應原性問題，並計劃將老年人群組納入I期臨床試驗。老年人群組的安全性和免疫原性結果預計於2024年下半年公布。公司股東及潛在投資者應審慎行事。
三葉草生物-B（股份代號：2197）自願公告其開發的二價RSV候選疫苗SCB-1019在I期臨床試驗中獲得積極初步數據。該試驗在澳大利亞進行，旨在評估該疫苗在不同年齡群組中的安全性、反應原性和免疫原性。首批年輕成年人群組（18-59歲）接種SCB-1019後，對RSV A和RSV B中和抗體的幾何平均滴度（GMTs）和幾何倍數升高（GMFRs）顯示出顯著提升，而安慰劑組則無明顯變化。這些數據顯示SCB-1019在免疫原性方面相較於其他蛋白亞單位RSV疫苗表現出相當或更優的效果。此外，該疫苗在首批受試者中未觀察到任何明顯的安全性或反應原性問題，並計劃將老年人群組納入I期臨床試驗。老年人群組的安全性和免疫原性結果預計於2024年下半年公布。公司股東及潛在投資者應審慎行事。
CLOVER BIO-B (STOCK CODE: 2197) VOLUNTARILY ANNOUNCES ITS DEVELOPMENT OF BIVALENT RSV CANDIDATE VACCINE SCB-1019 HAS RECEIVED POSITIVE PRELIMINARY DATA IN A PHASE I CLINICAL TRIAL. The trial, conducted in Australia, aims to assess the safety, responsiveness and immunogenicity of the vaccine in different age groups. After the first group of young adults (18-59 years old) received SCB-1019, a significant increase in geometric mean titration (GMTs) and geometric multiplicity elevations (GMFRs) of antibodies in RSV A and RSV B showed no significant change. These data show that SCB-1019 performed significantly or better in immunogenicity compared to other protein subunit RSV vaccines. In addition, no apparent safety or reactivity issues were observed in the first batch of the vaccine and it is planned to include the elderly group in Phase I clinical trials. Safety and immunogenicity results for the elderly population group are expected to be announced in the second half of 2024. Shareholders and potential investors should act with caution.
CLOVER BIO-B (STOCK CODE: 2197) VOLUNTARILY ANNOUNCES ITS DEVELOPMENT OF BIVALENT RSV CANDIDATE VACCINE SCB-1019 HAS RECEIVED POSITIVE PRELIMINARY DATA IN A PHASE I CLINICAL TRIAL. The trial, conducted in Australia, aims to assess the safety, responsiveness and immunogenicity of the vaccine in different age groups. After the first group of young adults (18-59 years old) received SCB-1019, a significant increase in geometric mean titration (GMTs) and geometric multiplicity elevations (GMFRs) of antibodies in RSV A and RSV B showed no significant change. These data show that SCB-1019 performed significantly or better in immunogenicity compared to other protein subunit RSV vaccines. In addition, no apparent safety or reactivity issues were observed in the first batch of the vaccine and it is planned to include the elderly group in Phase I clinical trials. Safety and immunogenicity results for the elderly population group are expected to be announced in the second half of 2024. Shareholders and potential investors should act with caution.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more